Intracranial metastases in small cell carcinoma of the lung. Correlation of clinical and autopsy findings

Abstract

Two hundred‐twelve consecutive patients with small cell carcinoma of the lung were included in an evaluation of clinical and diagnostic neurologic findings of intracranial metastases. A correlation of premortem findings to postmortem examination of the brain was obtained in 87 of the patients. Clinical intracranial metastases were diagnosed in 21.2% on the basis of symptoms and signs. At autopsy 44 of the 87 patients (50%) had metastases. Lesions located to the posterior cranial fossa were demonstrated in 53% of the positive autopsies. A correlation of 96% existed between significant premortem clinical findings and positive autopsy, while 33% had clinically “silent” metastases at autopsy. A neurooncologic examination was performed in 49 patients at the time of presentation of neurologic symptoms. Twenty‐eight patients were considered to have intracranial metastases. Gait disturbances were the presenting signs in more than 50% of the patients. Brain metastases were demonstrated at autopsy in 14 of 15 patients considered to have intracranial metastases by the neuro‐oncologist, and clinically “silent” metastases were observed in one out of 10 patients. Radionucleide brain scan was negative in seven of 13 patients in spite of “positive” neuro‐oncological examination and a subsequent positive autopsy. Cerebrospinal fluid examination was of no value in the diagnosis of brain metastases. It is concluded that a careful clinical examination by a neuro‐oncologist is of great value in early detection of brain metastases, especially in diagnosing metastases to the posterior cranial fossa.

Three Cases of Enduring Memory Impairment after Bilateral Damage Limited to the Hippocampal Formation

“…Multiple brain metastases are frequently observed with small-cell lung carcinoma (Hirsch et al, 1982), distributed more often in the frontal, parietal, and occipitotemporal regions than in the temporal or occipital lobes, and occasionally in the basal ganglia (Delattre et al, 1988). The metastases noted in LM's brain had a similar distribution (8 in frontal cortex, 11 in parietal cortex, 5 in temporal cortex, and 5 in occipitotemporal cortex).…”

Brain CT-scanning and neurological examination in small cell bronchogenic carcinoma

“…With prolonged survival the probability of CNS disease has increased from 15% at the time of diagnosis to 50% after one year, as reported by Nugent et al and Hirsch et al (3,4). At autopsy the frequency of CNS metastases is far greater than that diagnosed in vivo (5).…”

Update on small cell lung cancer management

“…A meta-analysis of PCI in patients with complete remission after systemic treatment demonstrated a slight survival benefit of above 5% with PCI [42]. In addition, a more recent phase III trial performed by SLOTMAN et al [50] in patients with extensive disease and performance status 0-2 showed that, in patients who responded to chemotherapy (not only patients with complete response), PCI decreased the incidence of brain metastases from 40.4% at 1 year to 14.6% (hazard ratio (HR) 0.27, 95% CI 0.16-0.44; p,0.0001) and gave a survival and symptomatic benefit with a 1-year survival rate of 13.3% in the control group and 27.1% in the treated group (HR 0.68, 95% CI 0.52-0.88; p50.003).…”